Literature DB >> 26372823

Helicobacter pylori and Gastrointestinal Malignancies.

Marino Venerito1, Riccardo Vasapolli1, Theodoros Rokkas2, Peter Malfertheiner1.   

Abstract

Helicobacter pylori infection is the principal trigger of gastric carcinogenesis and gastric cancer (GC) and remains the third leading cause of cancer-related death in both sexes worldwide. In a big Japanese study, the risk of developing GC in patients with peptic ulcer disease who received H. pylori eradication therapy and annual endoscopic surveillance for a mean of 9.9 years was significantly lower after successful eradication therapy compared to the group with persistent infection (0.21%/year and 0.45%/year, respectively, p = .049). According to a recent meta-analysis, H. pylori eradication is insufficient in GC risk reduction in subjects with advanced precancerous conditions (i.e., intestinal metaplasia and dysplasia). A microsimulation model suggested screening smokers over the age of 50 in the U.S. for serum pepsinogens. This would allow to detect advanced gastric atrophy with endoscopic follow-up of subjects testing positive as a cost-effective strategy to reduce GC mortality. In a Taiwanese study, the anti-H. pylori IgG-based test-and-treat program had lower incremental cost-effectiveness ratios than that with (13)C-urea breath test in both sexes to prevent GC whereas expected years of life lost for GC were higher and the incremental cost-effectiveness ratios of test-and-treat programs were more cost-effective in young adults (30-69 years old) than in elders (>70 years old). With respect to gastrointestinal malignancies other than GC, a meta-analysis confirmed the inverse association between H. pylori infection and esophageal adenocarcinoma. In a Finnish study, H. pylori seropositivity was associated with an increased risk of biliary tract cancers (multivariate adjusted OR 2.63; 95% CI: 1.08-6.37), another meta-analysis showed a slightly increased rate of pancreatic cancer in patients with CagA-negative strains (OR: 1.30; 95% CI: 1.02-1.65), whereas current data suggest that the association between H. pylori and colorectal neoplasms may be population dependent.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  colorectal cancer; gastric cancer; hepatobiliary malignancies; pancreatic cancer; prevention strategies; screening

Mesh:

Substances:

Year:  2015        PMID: 26372823     DOI: 10.1111/hel.12255

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  10 in total

1.  Correlation between Helicobacter pylori-associated gastric diseases and colorectal neoplasia.

Authors:  Ying Qing; Min Wang; Ying-Min Lin; Dong Wu; Jing-Yu Zhu; Lang Gao; Yan-Yan Liu; Teng-Fei Yin
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

Review 2.  Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis.

Authors:  Li-Jun Du; Bin-Rui Chen; John J Kim; Sarah Kim; Jin-Hua Shen; Ning Dai
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 3.  Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis.

Authors:  Giuseppe Losurdo; Rossella Cubisino; Michele Barone; Mariabeatrice Principi; Gioacchino Leandro; Enzo Ierardi; Alfredo Di Leo
Journal:  World J Gastroenterol       Date:  2018-01-07       Impact factor: 5.742

4.  Pilot study: Comparing efficacy of 14-day triple therapy Clarithromycin versus levofloxacin on eradication of Helicobacter pylori infection in Syrian population single-center experience.

Authors:  Khaled Mohammad Cheha; Sawsan Omar Ali Dib; Marouf Mohammad Alhalabi
Journal:  Avicenna J Med       Date:  2018 Jan-Mar

5.  Anti-bacterial effects of enzymatically-isolated sialic acid from glycomacropeptide in a Helicobacter pylori-infected murine model.

Authors:  Hye-Ji Noh; Hong Bum Koh; Hee-Kyoung Kim; Hyang Hyun Cho; Jeongmin Lee
Journal:  Nutr Res Pract       Date:  2016-12-27       Impact factor: 1.926

6.  Helicobacter pylori infection coexisting with intestinal metaplasia is not associated with colorectal neoplasms.

Authors:  Banu Boyuk; Arif Ozgur; Hande Atalay; Aslan Celebi; Ismail Ekizoglu; Engin Aykurt
Journal:  Prz Gastroenterol       Date:  2019-07-05

Review 7.  Diagnostic Ability of Magnifying Narrow-Band Imaging for the Extent of Early Gastric Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yingying Hu; Xueqin Chen; Maher Hendi; Jianmin Si; Shujie Chen; Yanyong Deng
Journal:  Gastroenterol Res Pract       Date:  2021-04-23       Impact factor: 2.260

Review 8.  Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?

Authors:  Javier Martinez-Useros; Jesus Garcia-Foncillas
Journal:  Biomed Res Int       Date:  2016-09-01       Impact factor: 3.411

9.  Nationwide population-based study reveals increased malignancy risk in taiwanese liver transplant recipients.

Authors:  Yung Fong Tsai; Hsiu Pin Chen; Fu Chao Liu; Shih Hao Liu; Chun Yu Chen; Chih Wen Cheng; Jr-Rung Lin
Journal:  Oncotarget       Date:  2016-12-13

Review 10.  Intestinal microbiota: a novel perspective in colorectal cancer biotherapeutics.

Authors:  Chenbo Ding; Wendong Tang; Xiaobo Fan; Guoqiu Wu
Journal:  Onco Targets Ther       Date:  2018-08-13       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.